Histone acetylation marks are written by histone acetyltransferases (HATs) and read by
bromodomains (BrDs), and less commonly by other protein modules. These proteins …

Histone deacetylases (HDACs)—enzymes that affect the acetylation status of histones and
other important cellular proteins—have been recognized as potentially useful therapeutic …

Over the last 5 years, a plethora of histone deacetylase inhibitors (HDACi) have been
evaluated in clinical trials. These drugs have in common the ability to hyperacetylate both …

The emergent interest in cancer epigenetics stems from the fact that epigenetic modifications
are implicated in virtually every step of tumorigenesis. More interestingly, epigenetic …

Acetylation is a key post-translational modification (PTM) involved in the regulation of both
histone and non-histone proteins. It controls cellular processes such as DNA transcription …

Histone deacetylases are considered to be among the most promising targets in drug
development for cancer therapy. Histone deacetylase 6 (HDAC6) is a unique cytoplasmic …

Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in
patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for …

Previous research reported that the curcumin derivative (CU17) inhibited several cancer cell
growths in vitro. However, its anticancer potential against human lung cancer cells (A549 …

Background Histone deacetylase (HDAC) inhibitors have shown radiosensitising activity in
preclinical tumour models. This phase 1 study assessed the use of vorinostat combined with …

Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell–or natural
killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience …